Genmab's multiple myeloma drug wins fast-track status

04/4/2013 | RTT News

The FDA granted fast-track status to daratumumab, an experimental multiple myeloma drug being developed by Genmab and Janssen Biotech. The designation covers patients who already received at least three lines of treatments including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a PI and an IMiD, this article says.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX